Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased

Share

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life.

Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health.

The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein.

This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily intake of spermidine. Spermidine is associated with benefits to longevity, cardiovascular health and brain health.

The paper states that “during (Almased’s) proteolytic enzyme procedure, bioactive and biogenic peptides, which were not detectable before in the raw materials, naturally occur. It can be assumed that the production process is significant in producing bioactive compounds responsible for unexpected positive effects on the metabolism, even in people who are not overweight”.

Other key findings in the 2022 review in Heliyon have shown:

  • 167% increase in GLP-1 production and a 358% increase in PYY production (a satiety-induced hormone produced in the intestine) compared to consuming a standard American diet containing the same amount of calories by the same individuals (Oliveira et al. 2022)
  • Almased group lost 145% more weight than the control group (-13lbs vs. -5.3lbs) in 12 weeks. Fat loss was 181% more in the Almased group (-9.9 lbs) than in the control group (-3.52 lbs) over the same period of time despite comparable weights before the study (Röhling et al. 2020)
  • Almased plus resistance training increased muscle strength by 33% versus resistance training alone (Deibert et al 2010)
  • Waist circumference reduction 239% greater in the Almased group compared to a fat-reduced diet (2.4in vs. 0.7in) after 6 weeks. Fat mass loss was 82% greater in the Almased group compared to a fat-reduced diet (11.2lbs vs. 6.1lbs) after 6 weeks (König et al 2008)
  • A study on post-menopausal women saw a 62% reduction in the prevalence of metabolic syndrome and significant fat loss without losing lean mass (Deibert et al. 2007)
  • Almased reduced liver fat content by an average of 56% and supports a healthy inflammatory response (Deibert et al 2019)
  • Almased preserved 100% muscle mass while losing weight (Deibert et al 2004)

Researchers found that Almased improves the fat burning process so you burn fat and calories more effectively (Oliveira et al 2021). In overweight and obese individuals, Almased meal replacement regimens resulted in greater reductions in body weight, body mass index (BMI), and fat mass compared to traditional low-calorie diets, while also improving glycemic control and lipid profiles.

Beyond weight management, the review highlights Almased’s role in supporting healthy blood sugar levels in both prediabetic and type 2 diabetic individuals. This indicates Almased is safe for people with diabetes.

The review also notes Almased’s unique anti-aging and wellness benefits. Regular use has been linked to healthy cell function, reduced stress markers, and better overall energy and mood. Almased’s protein-rich formula, containing essential amino acids and bioactive peptides, supports muscle preservation, cellular health, and supports a healthy inflammatory response, contributing to improved quality of life and longevity.

“The results presented underscore the efficacy of the soy-yogurt-honey formula (Almased) in weight management and the improvement of obesity-associated cardiovascular disease and metabolic risk factors.” said the study’s authors.

About Almased

Founded over 30 years ago in Germany by holistic therapist Hubertus Trouillé, and his son Andre Trouillé, Almased is a family-owned and operated company dedicated to promoting health and wellness worldwide. Recognized as Europe’s #1 science backed weight-loss meal replacement shake brand, Almased combines natural ingredients with a patented fermentation process to deliver high-quality, effective nutrition. With over 30 peer reviewed studies across 3 decades, Almased is a global leader in metabolic health. With a commitment to sourcing the highest quality ingredients in the world, Almased continues its mission to help people achieve healthier, happier lives with clean, sustainable products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250716374177/en/

Contacts

Melissa Tirey
melissa@shift6studios.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting Expands Platform with Addition of HTP Group16.7.2025 16:30:00 EEST | Press release

Andersen Consulting continues to expand its consulting capabilities with the addition of collaborating firm Hoffman Talent Partners (HTP Group), an executive search and consulting firm headquartered in Brussels, Belgium. HTP Group helps build impactful leaders for tomorrow’s organizations. HTP provides permanent talent through executive search, interim placements, and as-a-service models, along with leadership and IT consulting services. HTP Group operates through three entities: Hightech Partners, which specializes in executive search and leadership consulting for companies active in the area of digital transformation; Hoffman & Associates, which focuses on executive search and interim management across sectors and functions at board and executive-levels; and Ataya & Partners, which focuses on digital governance and provides cybersecurity and data protection consulting. “Organizations undergoing change require leadership that can keep pace with innovation while maintaining strategic c

Qualcomm Schedules Third Quarter Fiscal 2025 Earnings Release and Conference Call16.7.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its third quarter of fiscal 2025 on Wednesday, July 30, 2025, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its third quarter fiscal 2025 results which will be broadcast live on July 30, 2025, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/investor-events/default.aspx. An audio replay will be available at https://investor.qualcomm.com/news-events/investor-events/default.aspx and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international callers

Quectel Unveils High-Performance KCMA32S Zigbee & BLE Module for Smart Lighting, Building and Home Networks16.7.2025 16:00:00 EEST | Press release

Quectel Wireless Solutions, a global IoT solutions provider, has announced the launch of its latest high-performance MCU Zigbee and BLE module, the KCMA32S. This innovative module is designed to meet the growing demands of IoT applications, featuring advanced connectivity options and a compact form factor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716499223/en/ Quectel unveils high-performance KCMA32S Zigbee & BLE module for smart lighting, building and home networks Powered by Silicon Labs’ ultra-low-power EFR32MG21 wireless SoC, the KCMA32S module supports Zigbee 3.0 and BLE 5.3, enabling multi-protocol coexistence for enhanced communication capabilities. It is powered by an ARM Cortex-M33 processor with a frequency of up to 80 MHz, ensuring efficient performance for a wide range of applications. The module offers flexible memory configurations to suit various applications, with options of 64 KB RAM and 768 KB flas

Belgravia Hartford Announces USD$5M Convertible Secured Debenture with Round13 DAF & Closing of C$4M Private Placement16.7.2025 15:57:00 EEST | Press release

BELGRAVIA HARTFORD CAPITAL INC. (CSE:BLGV)(OTC:BLGVF)(FRA:ECA) ("Company" or “Belgravia”) is pleased to announce that: it has entered into a binding agreement with Round13 Digital Asset Fund (“Round13 DAF”) for a secured convertible debenture for a one-time principal amount investment of USD$5,000,000 (the “Debenture”) convertible into common shares at C$0.71, being a 40% premium to the volume-weighted average trading price (the “VWAP”) for the seven consecutive days immediately preceding the date of this announcement; and as a result of this above-market Debenture, Belgravia has elected to voluntarily reduce its non-brokered private placement to close on 16,091,822units (the “Units”) at a price of C$0.25 per Unit for aggregate gross proceeds of C$4,022,955.55(the “Offering”) to the Company. New USD$5 Million Round13 DAF Debenture Convertible at C$0.71 The principal amount and interest of the Debenture is convertible into common shares of Belgravia at a conversion price (the “Conversio

SLB Completes Acquisition of ChampionX16.7.2025 15:50:00 EEST | Press release

SLB (NYSE: SLB) announced today that it has closed its previously announced acquisition of ChampionX Corporation. Under the terms of the agreement, ChampionX shareholders received 0.735 shares of SLB common stock in exchange for each ChampionX share. With the closing of the transaction, former ChampionX shareholders now own approximately 9% of SLB’s outstanding shares of common stock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715857114/en/ The integration of ChampionX production chemicals and its complementary artificial lift, digital, and emissions technologies enhances the SLB portfolio, helping to drive performance and extend asset life along the production lifecycle. This strategic acquisition strengthens SLB's leadership in the production and recovery space. The integration of ChampionX production chemicals and its complementary artificial lift, digital, and emissions technologies enhances the SLB portfolio, hel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye